What is TB-500 studied for?

Published and ongoing research looks at soft-tissue and tendon injury models; scar-tissue remodeling and range-of-motion recovery; cardiac and corneal repair in animal research; inflammatory signaling around chronic injury sites. These are areas of study, not promised outcomes.

Is TB-500 FDA-approved?

TB-500 has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.

How is TB-500 typically used?

Typically discussed in loading-then-maintenance research patterns Commonly discussed alongside BPC-157 because the mechanisms are complementary Not a substitute for imaging, diagnosis or structured rehab Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.

What are the risks and unknowns with TB-500?

Not FDA-approved and not available through licensed compounding pharmacies Human safety and dosing data are limited to case reports Prohibited in competitive sport under WADA rules Same growth-signaling caution applies for anyone with cancer history

Repair & recovery

TB-500

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending.

See the FDA 503A status tracker

Also known as Thymosin Beta-4 fragment

A fragment of thymosin beta-4 studied for cell migration, flexibility and scar remodeling in preclinical injury models.

What it is

Thymosin beta-4 is a naturally occurring protein involved in actin regulation — the machinery cells use to move. TB-500 is a synthetic fragment of that protein. Research interest centers on cell migration into injured tissue, new vessel formation and reduced fibrotic scarring.

What it's studied for

Soft-tissue and tendon injury models
Scar-tissue remodeling and range-of-motion recovery
Cardiac and corneal repair in animal research
Inflammatory signaling around chronic injury sites

How it's used in practice

Typically discussed in loading-then-maintenance research patterns
Commonly discussed alongside BPC-157 because the mechanisms are complementary
Not a substitute for imaging, diagnosis or structured rehab

What you should know before asking about it

Not FDA-approved and not available through licensed compounding pharmacies
Human safety and dosing data are limited to case reports
Prohibited in competitive sport under WADA rules
Same growth-signaling caution applies for anyone with cancer history

Frequently asked questions.

What is TB-500?: Thymosin beta-4 is a naturally occurring protein involved in actin regulation — the machinery cells use to move. TB-500 is a synthetic fragment of that protein. Research interest centers on cell migration into injured tissue, new vessel formation and reduced fibrotic scarring.
What is TB-500 studied for?: Published and ongoing research looks at soft-tissue and tendon injury models; scar-tissue remodeling and range-of-motion recovery; cardiac and corneal repair in animal research; inflammatory signaling around chronic injury sites. These are areas of study, not promised outcomes.
Is TB-500 FDA-approved?: TB-500 has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
How is TB-500 typically used?: Typically discussed in loading-then-maintenance research patterns Commonly discussed alongside BPC-157 because the mechanisms are complementary Not a substitute for imaging, diagnosis or structured rehab Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
What are the risks and unknowns with TB-500?: Not FDA-approved and not available through licensed compounding pharmacies Human safety and dosing data are limited to case reports Prohibited in competitive sport under WADA rules Same growth-signaling caution applies for anyone with cancer history

Sources

1.Published literature on TB-500 Thymosin Beta-4 fragment— PubMed, U.S. National Library of Medicine
2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
4.Test directory and patient service center locator— Quest Diagnostics

About this page

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.

This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.

Begin your intake Peptide therapy overview